0000000000560285

AUTHOR

Vicente Alberola

showing 2 related works from this author

Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients.

2006

Abstract Background: Impaired DNA repair capacity may favorably affect survival in cisplatin/gemcitabine-treated non-small-cell lung cancer (NSCLC) patients. We investigated the association of survival with genetic polymorphisms in X-ray repair cross-complementing group 1 and group 3 (XRCC3), xeroderma pigmentosum group D (XPD), excision repair cross-complementing group 1, ligase IV, ribonucleotide reductase, TP53, cyclooxygenase-2, interleukin-6, peroxisome proliferator-activated receptor γ, epidermal growth factor, methylene-tetra-hydrofolate reductase and methionine synthase. Patients and methods: One hundred and thirty-five stage IV or IIIB (with malignant pleural effusion) NSCLC patien…

Xeroderma pigmentosumLung NeoplasmsDNA RepairGenotypeDeoxycytidineXRCC1Carcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansCisplatin; DNA repair genes; Gemcitabine; Non-small-cell lung cancer; Polymorphisms; XRCC3Lung cancerXRCC3Survival analysisCisplatinPolymorphism GeneticDNA repair genesbusiness.industryHazard ratioHematologymedicine.diseaseSurvival AnalysisGemcitabineGemcitabineOncologyCancer researchCisplatinbusinessPolymorphismsNon-small-cell lung cancerNucleotide excision repairmedicine.drugAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Quantitative monoclonal antibody determination of estrogen and progesterone receptors in human breast cancer: correlation with the radioligand method.

1994

To assess the possibility of substituting our routine method (dextran-coated charcoal, DCC) of determining estrogen (ER) and progesterone receptors (PR) for an enzyme immunoassay technique (EIA), we compared the two methods for determination of the two types of receptor in breast cancer specimens. In terms of sample positivity or negativity, the two techniques agreed in 76 of the 82 samples analyzed for ER (92.7%; p0.001), and in 65 out of 75 samples assayed for PR (86.6%; p0.001). Quantitative analysis of the data showed a significant correlation between DCC and EIA for both ER (r = 0.84; p0.0001) and PR (r = 0.77; p0.0001). The results suggest the usefulness of EIA in substituting DCC, al…

Cancer Researchmedicine.medical_specialtymedicine.drug_classMammary glandEstrogen receptorBreast NeoplasmsBiologyMonoclonal antibodyRadioligand AssayInternal medicineProgesterone receptormedicineRadioligandHumansReceptorfungiAntibodies MonoclonalGeneral MedicineRadioligand AssayEndocrinologymedicine.anatomical_structureOncologyReceptors EstrogenEstrogenFemaleReceptors Progesteronehormones hormone substitutes and hormone antagonistsOncology
researchProduct